Urology Scientific References
Fertility | Women's Health | Urology | Rheumatology | General Health
LATEST RESEARCH UPDATE: The recently published AUA Guideline for “Recurrent Uncomplicated Urinary Tract Infections in Women” recommends cranberry prophylaxis. Specifically, Guideline Statement 13 is “Clinicians may offer cranberry prophylaxis for women with rUTIs.” The Guideline reviews the cranberry research and mechanism of action: the ability of proanthocyanidins (PACs) to prevent bacterial adhesion to the uroepithelium. The Panel notes the variability in PAC concentration of cranberry products available and points out the lack of regulation in the dietary supplement industry. Cranberry is the only non-antibiotic prophylaxis that the AUA Guideline recommends. For more information check out the guidline abstract.
Bladder Health
(2014/04) Vitamin A and risk of bladder cancer: a meta-analysis of epidemiological studies.
(2008/11) Plasma vitamins E and A and risk of bladder cancer: a case-control analysis.
(2004/04) The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder.
(2003/10) Serum vitamins and the subsequent risk of bladder cancer.
(2002/10) Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study.
(2001/12) Retinoids in the prevention of bladder cancer.
(1995/01) Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland.
(1994/01) Megadose vitamins in bladder cancer: a double-blind clinical trial.
(2018/10) Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.
(2016/05) Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis.
(2015/05) Vitamin D Deficiency and Increased Risk of Bladder Carcinoma: A Meta-Analysis.
(2015/04) Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: a dose-response meta-analysis.
(2015/03) Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis.
(2013/03)Relationship of vitamin D monitoring and status to bladder cancer survival in veterans.
Urinary Tract Health
(2019/05) Recurrent Uncomplicated Urinary Tract Infections In Women: AUA/CUA/SUFU Guideline.
(2018/10) Cranberry Standardized Capsules May Prevent Recurrences of Urinary Tract Infections in Children.
(2017/12) Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis.
(2017/09) Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials.
(2016/11) Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes: A Randomized Clinical Trial.
(2016/09) Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study.
(2016/06) Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection.
(2015/12) Cranberry Products for the Prophylaxis of Urinary Tract Infections in Pediatric Patients.
(2015/08) Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial.
(2015/01) Cranberry supplementation in the prevention of non-severe lower urinary tract infections: a pilot study.
(2014/01) Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities.
(2012/10) Cranberries for preventing urinary tract infections.
(2012/07) Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials.
(2011/06) Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin
(2011/01) Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial
(2009/07) Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration
(2009/02) Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women
(2008/10) Daily cranberry juice for the prevention of asymptomatic bacteriuria in pregnancy: a randomized, controlled pilot study.
(2007/06) Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells.
(2007/04) Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: a pilot double-blind placebo-controlled trial.
(2006/02) Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial.
(2005/11) Inhibition of uropathogenic Escherichia coli by cranberry juice: a new antiadherence assay.
(2005/09) A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity.
(2005/05) Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial.
(2002/06) A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women.
(2001/06) Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women.
(1998/10) Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries.
Urine Chemistry
(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.
(2012/10) High dietary magnesium intake decreases hyperoxaluria in patients with nephrolithiasis
(2005/06) Magnesium therapy for nephrolithiasis.
(2005/03) Importance of magnesium in absorption and excretion of oxalate.
(2004/01) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
(1994/03) Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers
(1992/03) Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
(1990/02) Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction.
(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.
(2009/03) Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation
(2004/01) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
(1997/12) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis
(1993/12) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium
(1992/03) Physicochemical action of potassium-magnesium citrate in nephrolithiasis
(1991/02) Contrasting effects of various potassium salts on renal citrate excretion.
(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.
(2011/05) Pyridoxine and Dietary Counseling for the Management of Idiopathic Hyperoxaluria in Stone-forming Patients.
(2005/02) Effect of pyridoxine (vitamin B6) supplementation on calciuria and oxaluria levels of some normal healthy persons and urinary stone patients
(1999/04) Intake of vitamins B6 and C and the risk of kidney stones in women.
(1996/06) A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men
(1994/12) Effect of combined supplementation of magnesium oxide and pyridoxine in calcium oxalate stone formers
Prostate Health
(2000/05) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
(2000/01) Beta-sitosterols for benign prostatic hyperplasia.
(1999/06) Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
(1997/09) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
(1995/06) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
(2017/01) Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.
(2015/01) Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.
(2015/01) Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies.
(2017/12) Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.
(2017/06) Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.
(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.
(2009/03) Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
(2007/09) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study.
(2006/03) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States).
(2005/11) Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
(2004/09) Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer
(2003/11) Prostate Carcinogenesis in N-methyl-N-nitrosourea(NMU)- Testosterone-Treated Rats Fed Tomato Powder, Lycopene, or Energy-Restricted Diets
(2003/09) A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer.
(2002/11) Effects of lycopene supplementation in patients with localized prostate cancer.
(2002/11) Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis.
(2002/03) A prospective study of tomato products, lycopene, and prostate cancer risk
(2001/08) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.
(1995/12) Intake of carotenoids and retinol in relation to risk of prostate cancer.
(2016/07) Omega-3 Fatty Acid Consumption and Prostate Cancer: A Review of Exposure Measures and Results of Epidemiological Studies.
(2014/01) Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy.
(2013/08) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
(2011/12) Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy.
(2007/01) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism.
(2007/01) Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.
(2006/03) Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs.
(2006/03) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States).
(2004/12) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.
(2004/07) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer
(2019/01)The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids.
(2018/04)Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
(2017/04) The role of flower pollen extract in managing patients affected by chronic prostatitis/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials..
(2014/01) Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome.
(2013/04) Effects of pollen extract in association with vitamins (DEPROX 500®) for pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome: results from a pilot study.
(2011/08) Pollen extract for chronic prostatitis-chronic pelvic pain syndrome.
(2009/09) A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, prospective, double-blind, placebo-controlled phase 3 study.
(2006/01) Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study.
(2015/12) Effects of hexanic extract of serenoa repens (permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
(2015/07) Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
(2013/12) Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
(2013/08) The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia
(2013/04) Safety and toxicity of saw palmetto in the CAMUS trial.
(2013/02) Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial.
(2012/09) Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
(2012/06) Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation.
(2012/02) The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.
(2011/09) Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
(2011/03) Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia.
(2010/09) Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia.
(2007/03) A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.
(2005/03) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
(2004/06) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
(2002/06) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
(1996/10) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
(2017/02) Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis.
(2016/07) Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.
(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.
(2015/10) Cancer Chemoprevention Research with Selenium in the Post-SELECT Era: Promises and Challenges.
(2013/04) Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).
(2012/07) Selenium and prostate cancer: systematic review and meta-analysis.
(2009/08) Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer
(2009/01) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial
(2004/05) A prospective study of plasma selenium levels and prostate cancer risk.
(2003/05) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.
(2003/02) Serum selenium and risk of prostate cancer in U.S. blacks and whites.
(2002/11) Influence of Selenium-enriched Yeast Supplementation on Biomarkers of Oxidative Damage and Hormone Status in Healthy Adult Males: A Clinical Pilot Study.
(1998/05) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.
(2019/01) Soy Isoflavones Protect Normal Tissues While Enhancing Radiation Responses.
(2018/01) Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
(2016/07) Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases.
(2015/11)Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.
(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.
(2011/07) Soy isoflavones sensitize cancer cells to radiotherapy
(2010/10) Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.
(2010/07) Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.
(2010/06) A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer.
(2010/01) Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells.
(2008/05) Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
(2007/08) Dietary isoflavones may protect against prostate cancer in Japanese men.
(2007/06) Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model.
(2006/06) Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men.
(2004/05) The specific role of isoflavones in reducing prostate cancer risk.
(2003/11) Soy Isoflavones in the Treatment of Prostate Cancer
(2002/10) Genestein and vitamin D synergistically inhibit human prostatic epithelial cell growth.
(2001/02) Genetein Potentiates the Radiation Effect on Prostate Carcinoma Cells
(1998/12) Does high soy milk intake reduce prostate cancer incidence?
(2018/10) Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis.
(2018/10) Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.
(2017/07) Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
(2017/03) Low vitamin D status is associated with inflammation in patients with prostate cancer.
(2017/01) Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.
(2016/12) Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men.
(2016/04) Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.
(2016/04) Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.
(2016/01) A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.
(2016/01) Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study.
(2014/08) Serum 25-Hydroxyvitamin D concenrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
(2014/01) Vitamin D and prostate cancer survival in veterans.
(2012/05) Vitamin d-related genetic variation, plasma vitamin d, and risk of lethal prostate cancer: a prospective nested case-control study.
(2012/04) Vitamin D3 Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance.
(2011/10) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.
(2011/10) Vitamin D deficiency in the urological population: a single center analysis
(2011/09) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study
(2009/01) Association between serum 25(OH)D and death from prostate cancer
(2006/09) Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer.
(2005/01) Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
(2004/01) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk
(2002/03) An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation.
(2015/11) Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.
(2014/05) Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.
(2012/04) Does Vitamin E Prevent or Promote Cancer?
(2011/10) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial
(2009/01) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial
(2008/02) Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.
(2005/03) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.
(2003/07) Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation
(2001/12) Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention.
(2000/12) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer.
(1999/10) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States.
(1998/03) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial.
